Form 8-K NGM BIOPHARMACEUTICALS For: Feb 25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Citi Downgrades NGM Biopharmaceuticals (NGM) to Neutral
February 27, 2024 8:47 AM ESTCiti analyst Samantha Semenkow downgraded NGM Biopharmaceuticals (NASDAQ: NGM) from Buy to Neutral with a price target of $1.55 (from $6.00).
The analyst comments "NGM announced the company has entered into a merger agreement with affiliates of The Column Group (i.e., Atlas Neon... More



